Physician profile
Michael J Rayno
NPI 1801841879
$1,169.55
in general payments reported to CMS, 2019-2025
13 companies · $23.50 in 2025
The $23.50 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $87.85 · 2021: $126 · 2022: $257 · 2023: $266 · 2024: $194 · 2025: $23.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $483.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $627.22 | 2019-2024 | Citrefix, Augment Injectable, Easyfuse |
| Kerecis Limited | $127.26 | 2021-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| In2bones USA, LLC | $117.05 | 2022 | |
| Organogenesis INC. | $92.21 | 2019-2023 | Puraply |
| Polynovo North America LLC | $36.77 | 2024 | Novosorb Btm |
| Bioventus LLC | $33.45 | 2023 | Exogen Ultrasound Bone Healing System |
| Abbvie INC. | $27.38 | 2022 | |
| Lifenet Health | $23.50 | 2025 | Theragenesis Wound Matrix |
| Convatec INC. | $22.93 | 2024 | |
| Solventum Corporation | $18.62 | 2024 | V.A.C. Granufoam, V.A.C. Dermatac |
| Depuy Synthes Sales INC. | $15.49 | 2020 | |
| Boston Scientific Corporation | $14.49 | 2023 | |
| Horizon Therapeutics Plc | $13.18 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rayno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.